Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors

    Cancer Categories
    • Breast,Gynecologic,Lung
    Karmanos Trial ID
    • 2022-088
    NCT ID
    • NCT05579366
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator
    • Image of Ira Winer , MD, PhD, FACOG
      Ira
      Winer, MD, PhD, FACOG
      Oncology - Gynecologic, Oncology - Surgical View Profile

    Objective:

    Primary Objectives:

    • Evaluate the safety and tolerability of PRO1184 in patients with locally advanced and/or metastatic solid tumors
    • Identify the maximum tolerated dose (MTD), if reached, and the recommended Phase 2 dose (RP2D) of PRO1184 in patients with locally advanced and/or metastatic solid tumors

    Secondary Objectives

    • Assess the antitumor activity of PRO1184
    • Assess the pharmacokinetics (PK) of PRO1184
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266